摘要
药物及对症支持治疗仍然是原发性骨髓纤维化(PMF)的主要治疗方法,但是其仅能改善患者症状而无法改变PMF的自然病程,而造血干细胞移植是目前治愈PMF唯一有效的手段.然而,严重的移植相关并发症限制了其在PMF患者中的广泛开展.文章就PMF患者造血干细胞移植过程中供者的选择、预处理方式、影响移植成功的因素等作一综述.
Drugs and symptomatic and supportive treatment are still the main treatment in the primary myelofibrosis (PMF),but they can only improve symptoms without the natural course change of PMF.Hematopoietic stem cell transplantation (HSCT) is the only curable means to PMF,however,serious transplantrelated complications limit its extensive application in PMF patients.In this paper,donor selection process,pretreatment,successful transplantation factors and other factors on HSCT in PMF patients will be reviewed.
出处
《白血病.淋巴瘤》
CAS
2016年第5期314-317,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金,江苏省重点研发计划(BL2012022) National Natural Science Foundation of China,Key Plan of Research and Development of Jiangsu Province
关键词
原发性骨髓纤维化
造血干细胞移植
Primary myelofibrosis
Hematopoietic stem cell transplantation